Results 251 to 260 of about 42,993 (314)

Neuroplasticity and neuroimmune interactions with type 2 inflammation in asthma. [PDF]

Eur Respir Rev
Koster CS, Lavitola C, Teodorescu R, Bakker BA, Gosens R.   +4 more
europepmc   +1 more source

Adiabatic-Bias Molecular Dynamics Simulations Reveal the Impact of Mutations on Muscarinic Antagonist Unbinding Kinetics

Adriana Coricello, Anna Lisa Chiaravalle, Maria Musgaard, Benjamin G. Tehan, Gian Marco Elisi, Giovanni Bottegoni   +5 more
openalex   +1 more source

Dopamine and Acetylcholine in the Striatum: Circuit Interactions and Behavioral Control in Substance Use Disorders. [PDF]

Brain Sci
Dinckol O, Wenger NH, Copling A, Patel BP, Kutlu MG.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Long-acting muscarinic antagonists

Expert Review of Clinical Pharmacology, 2015
Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment. Long-acting muscarinic antagonists (LAMAs) are a major class of inhaled bronchodilators.
Andrea S Melani
exaly   +3 more sources

Role of muscarinic antagonists in asthma therapy

Expert Review of Respiratory Medicine, 2017
Higher parasympathetic tone has been reported in asthmatics. In general, cholinergic contractile tone is increased by airway inflammation associated with asthma. Nevertheless, the role of muscarinic antagonists for the treatment of asthma has not yet been clearly defined.
Mario Cazzola, JosuéL Ora, Paola Rogliani   +2 more
exaly   +6 more sources

Muscarinic Receptor Antagonists

2016
Parasympathetic activity is increased in patients with chronic obstructive pulmonary disease (COPD) and asthma and appears to be the major reversible component of airway obstruction. Therefore, treatment with muscarinic receptor antagonists is an effective bronchodilator therapy in COPD and also in asthmatic patients.
Maria Gabriella, Matera, Mario, Cazzola
openaire   +2 more sources

Selective Muscarinic Receptor Agonists and Antagonists

Pharmacology & Toxicology, 1996
Abstract:Muscarinic receptors are composed of a family of four subtypes each of which can be distinguished pharmacologically and structurally. The physiological role of each subtype in the central and peripheral nervous systems remains to be clarified, due, in part, to a lack of agonists and antagonists with adequate subtype selectivity.
R M, Eglen, N, Watson
openaire   +2 more sources

Quinidine as a muscarinic antagonist: A structural approach

Journal of Pharmaceutical Sciences, 1992
The synthesis, spectroscopic characteristics, and single-crystal X-ray structural analysis of quitenidine methyl ester monohydrate, a derivative of the muscarinic antagonist quinidine, are presented. Quitenidine methyl ester monohydrate (C20H24N2O4.H2O) crystallizes in the orthorhombic space group P2(1)2(1)2(1), with a = 16.69(3) A, b = 12.46(2) A, c =
M, Ciechanowicz-Rutkowska, B J, Oleksyn, A, Suszko-Purzycka, T, Lipińska   +3 more
openaire   +2 more sources